FutureChem
FutureChem is a South Korea-based radiopharmaceutical company running 2 late-stage cancer trials of [F-18]Florastamin in prostate cancer.
Overview
FutureChem, based in Seoul, South Korea, is a radiopharmaceutical company. FUTURECHEM is a radiopharmaceutical drug-development company specialising in PET diagnostic imaging agents for neurological and oncological conditions. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials (2 in phase 3), testing [F-18]Florastamin in prostate cancer. The largest, NCT05004285 (Evaluate the Clinical Usefulness of [F-18]Florastamin PET/CT Imaging Diagnosis Compared to MRI Diagnosis), plans to enrol 398 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry, checked on 2026-09-11; company facts are from the official website.
Similar pages
not linked directly; found by shared links- CompanyHinova Pharmaceuticals
Shares Prostate cancer and the tag ctgov-sponsor.
- CompanySpectraCure
Shares Prostate cancer and the tag ctgov-sponsor.
- CompanyOrion, Orion Pharma
Shares Prostate cancer and the tag ctgov-sponsor.
- CompanyMBrace Therapeutics
Shares Prostate cancer and the tag ctgov-sponsor.
- CompanyShenzhen Ionova Life Sciences
Shares Prostate cancer and the tag ctgov-sponsor.
- CompanyEvopoint Biosciences
Shares Prostate cancer and the tag ctgov-sponsor.
- CompanyNuvation Bio
Shares Prostate cancer and the tag ctgov-sponsor.
- CompanyOncoC4
Shares Prostate cancer and the tag ctgov-sponsor.